

Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M4DA0C4220A5EN.html>

Date: March 2022

Pages: 136

Price: US\$ 2,000.00 (Single User License)

ID: M4DA0C4220A5EN

Abstracts

Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 9, 5, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).

The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myasthenia Gravis

(Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Myasthenia Gravis - Overview
- Myasthenia Gravis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Myasthenia Gravis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Myasthenia Gravis - Companies Involved in Therapeutics Development
- Ahead Therapeutics SL
- Akari Therapeutics Plc
- Alexion Pharmaceuticals Inc
- Alpha Cancer Technologies Inc
- Amneal Pharmaceuticals Inc
- Amplo Biotechnology Inc
- AnToIRx Inc
- Argenx SE
- Beijing Mabworks Biotech Co Ltd
- BioMarin Pharmaceutical Inc
- BioXpress Therapeutics SA
- Cabaletta Bio Inc
- Cartesian Therapeutics Inc
- Chord Therapeutics Sarl
- Chugai Pharmaceutical Co Ltd
- Cour Pharmaceuticals Development Co Inc
- CSL Ltd
- CuraVac Inc
- Cytodyn Inc
- DAS Therapeutics Inc
- HanAll Biopharma Co Ltd
- Horizon Therapeutics Plc

ImmunAbs Inc
Johnson & Johnson
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Ltd
Medytox Inc
MetVital Inc
NeoProgen Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
NMD Pharma AS
Novartis AG
Oak Hill Bio Inc
Pfizer Inc
PlateletBio
Principia Biopharma Inc
Protalex Inc
Ra Pharmaceuticals Inc
Rallybio Corp
ReceptoPharm Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Taxon Therapeutics Ltd
Toleranzia AB
UCB SA
Yantai Rongchang Pharmaceutical Co Ltd
Myasthenia Gravis - Drug Profiles
(ondansetron + pyridostigmine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALXN-2050 - Drug Profile
Product Description
Mechanism Of Action

History of Events

amifampridine phosphate - Drug Profile

Product Description

Mechanism Of Action

History of Events

AMP-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Anhydrous enol oxaloacetate - Drug Profile

Product Description

Mechanism Of Action

AT-1616 - Drug Profile

Product Description

Mechanism Of Action

B-20672 - Drug Profile

Product Description

Mechanism Of Action

batoclimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

cladribine - Drug Profile

Product Description

Mechanism Of Action

CSL-730 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVMG-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Descartes-08 - Drug Profile

Product Description

Mechanism Of Action

History of Events

eculizumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

History of Events

gefurulimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target MuSK for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene-Modified Cell Therapy for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

IM-101 - Drug Profile

Product Description

Mechanism Of Action

inebilizumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

iscalimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

K-127 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KIMS-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KPL-404 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ieronlimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

methotrexate - Drug Profile

Product Description

Mechanism Of Action

History of Events

mezagitamab - Drug Profile

Product Description

Mechanism Of Action

History of Events

MIL-62 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MT-927 - Drug Profile

Product Description

Mechanism Of Action

nipocalimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

NMDP-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

nomacopan - Drug Profile

Product Description

Mechanism Of Action

History of Events

NPO-15 - Drug Profile

Product Description

Mechanism Of Action

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

OHB-201 - Drug Profile

Product Description

Mechanism Of Action

History of Events

orilanolimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-06755347 - Drug Profile

Product Description

Mechanism Of Action

History of Events

pozelimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Protein for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

PRTX-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ravulizumab LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar 1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RLYB-116 - Drug Profile

Product Description

Mechanism Of Action

History of Events

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

RPI-78M - Drug Profile

Product Description

Mechanism Of Action

satralizumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Cardiovascular Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Alzheimer's Disease and Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

telitacicept - Drug Profile

Product Description

Mechanism Of Action

History of Events

TOL-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tolebrutinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

zilucoplan - Drug Profile

Product Description

Mechanism Of Action

History of Events

zilucoplan XR - Drug Profile

Product Description

Mechanism Of Action

History of Events

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Featured News & Press Releases

Mar 01, 2022: U.S. Food and Drug Administration grants Cabaletta Bio fast track designation for MuSK-CAART

Feb 14, 2022: Argenx's Vyvgart offers a substantial advance over other treatments for generalized myasthenia gravis, spherix survey suggests

Feb 04, 2022: UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan 24, 2022: Soleo Health selected as limited distribution partner for VYVGART

Jan 20, 2022: argenx announces VYVGART approval in Japan for the treatment of generalized myasthenia gravis

Jan 03, 2022: More than two decades of UTSW research paves way for first-in-kind drug

Dec 31, 2021: Hanall Biopharma's partner Immunovant to start phase 3 clinical trial for myasthenia gravis in the first half of next year

Dec 30, 2021: Immunovant provides regulatory update regarding initiation of phase 3 trial for batoclimab in Myasthenia Gravis in the first half of 2022

Dec 21, 2021: Submission based on positive phase III trial in which Ultomiris significantly improved functional activities as measured by myasthenia gravis-activities of daily living profile

Dec 17, 2021: Zai Lab partner argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART (efgartigimod alfa-fcab) in generalized myasthenia gravis

Dec 14, 2021: RemeGen reiterates commitment to its battle against autoimmune disease on World Strengthened Immunity Day 2021

Dec 10, 2021: UCB announces positive Phase 3 results for rozanolixizumab in

generalized myasthenia gravis

Nov 11, 2021: Start of Toleranzia's planned clinical trial with TOL2 postponed due to global shortage of certain materials for production of the drug substance

Oct 19, 2021: Harbour BioMed announces dosing of first patient of batoclimab phase II trial in patients with thyroid eye disease

Oct 08, 2021: argenx to highlight potential first-in-class FcRn antagonist Efgartigimod at upcoming Neuromuscular Meetings

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myasthenia Gravis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Myasthenia Gravis - Pipeline by Ahead Therapeutics SL, 2022
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, 2022
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, 2022
Myasthenia Gravis - Pipeline by Amneal Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Amplo Biotechnology Inc, 2022
Myasthenia Gravis - Pipeline by AnToIRx Inc, 2022
Myasthenia Gravis - Pipeline by Argenx SE, 2022
Myasthenia Gravis - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, 2022
Myasthenia Gravis - Pipeline by BioXpress Therapeutics SA, 2022
Myasthenia Gravis - Pipeline by Cabaletta Bio Inc, 2022
Myasthenia Gravis - Pipeline by Cartesian Therapeutics Inc, 2022
Myasthenia Gravis - Pipeline by Chord Therapeutics Sarl, 2022
Myasthenia Gravis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Myasthenia Gravis - Pipeline by CSL Ltd, 2022
Myasthenia Gravis - Pipeline by CuraVac Inc, 2022
Myasthenia Gravis - Pipeline by Cytodyn Inc, 2022
Myasthenia Gravis - Pipeline by DAS Therapeutics Inc, 2022
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, 2022

Myasthenia Gravis - Pipeline by Horizon Therapeutics Plc, 2022
Myasthenia Gravis - Pipeline by ImmunAbs Inc, 2022
Myasthenia Gravis - Pipeline by Johnson & Johnson, 2022
Myasthenia Gravis - Pipeline by KIMS Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Myasthenia Gravis - Pipeline by Medytox Inc, 2022
Myasthenia Gravis - Pipeline by MetVital Inc, 2022
Myasthenia Gravis - Pipeline by NeoProgen Inc, 2022
Myasthenia Gravis - Pipeline by Neurotune AG, 2022
Myasthenia Gravis - Pipeline by Nihon Pharmaceuticals Co Ltd, 2022
Myasthenia Gravis - Pipeline by NMD Pharma AS, 2022
Myasthenia Gravis - Pipeline by Novartis AG, 2022
Myasthenia Gravis - Pipeline by Oak Hill Bio Inc, 2022
Myasthenia Gravis - Pipeline by Pfizer Inc, 2022
Myasthenia Gravis - Pipeline by PlateletBio, 2022
Myasthenia Gravis - Pipeline by Principia Biopharma Inc, 2022
Myasthenia Gravis - Pipeline by Protalex Inc, 2022
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Rallybio Corp, 2022
Myasthenia Gravis - Pipeline by ReceptoPharm Inc, 2022
Myasthenia Gravis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Samsung Bioepis Co Ltd, 2022
Myasthenia Gravis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Myasthenia Gravis - Pipeline by Taxon Therapeutics Ltd, 2022
Myasthenia Gravis - Pipeline by Toleranzia AB, 2022
Myasthenia Gravis - Pipeline by UCB SA, 2022
Myasthenia Gravis - Pipeline by Yantai Rongchang Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Dormant Projects, 2022
Myasthenia Gravis - Dormant Projects, 2022 (Contd..1)
Myasthenia Gravis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Myasthenia Gravis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M4DA0C4220A5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M4DA0C4220A5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

